(aR,BS)-rel-Bedaquiline is a promising diarylquinoline candidate in clinical development for the treatment of tuberculosis. (aR,BS)-rel-Bedaquiline inhibits mycobacterial ATP synthase and displays high activity against both drug-susceptible and multidrug-resistant strains of Mycobacterium tuberculosis.Melting Point: 181-183°CSolubility:Chloroform, Ethyl Acetate